Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis

References

• International Diabetes Federation. 5th Edition of the Diabetes Atlas released on World Diabetes Day. Available from http://www.idf.org/media-events/press-releases/2011/diabetes-atlas-5th-edition.
   Google Scholar
• Lam EK, Batty GD, Huxley RR, Martiniuk AL, Barzi F, Lam TH, Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Ann Oncol 2011;22:730–8.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674–85.
   PubMed Web of Science ®Google Scholar
• Chen TM, Lin CC, Huang PT, Wen CF. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2011;26:858–65.
   PubMed Web of Science ®Google Scholar
• Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999;91:542–7.
   PubMed Web of Science ®Google Scholar
• Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5–S16.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005;14:243–50.
   PubMed Web of Science ®Google Scholar
• Gao C, Zhao HC, Li JT, Yao SK. Diabetes mellitus and hepatocellular carcinoma: comparison of Chinese patients with and without HBV-related cirrhosis. World J Gastroenterol 2010;16:4467–75.
   PubMedGoogle Scholar
• El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460–8.
   PubMed Web of Science ®Google Scholar
• Adami HO, Chow WH, Nyrén O, Berne C, Linet MS, Ekbom A, Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996;88:1472–7.
   PubMed Web of Science ®Google Scholar
• Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25–33.
   PubMed Web of Science ®Google Scholar
• Aljada A, Mousa SA. Metformin and neoplasia: implications and indications. Pharmacol Ther 2012;133:108–15.
   PubMed Web of Science ®Google Scholar
• Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2010;32:1211–21.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574–9.
   PubMed Web of Science ®Google Scholar
• Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008;5:157–67.
   PubMed Web of Science ®Google Scholar
• Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 2010;3:1060–5.
   PubMed Web of Science ®Google Scholar
• Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3:1451–61.
   PubMed Web of Science ®Google Scholar
• Hede K. Doctors seek to prevent breast cancer recurrence by lowering insulin levels. J Natl Cancer Inst 2008;100:530–2.
   PubMedGoogle Scholar
• Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011;54:25–31.
   PubMed Web of Science ®Google Scholar
• Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482–8.
   PubMed Web of Science ®Google Scholar
• Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010;30:750–8.
   PubMed Web of Science ®Google Scholar
• Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 2010;6:457–70.
   PubMed Web of Science ®Google Scholar
• Vakana E, Altman JK, Platanias LC. Targeting AMPK in the treatment of malignancies. J Cell Biochem 2012;113:404–9.
   PubMedGoogle Scholar
• Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011;9:33.
   PubMed Web of Science ®Google Scholar
• Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304–5.
   PubMed Web of Science ®Google Scholar
• Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254–8.
   PubMed Web of Science ®Google Scholar
• Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009;15:2506–11.
   PubMed Web of Science ®Google Scholar
• Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010;116:1938–46.
   PubMed Web of Science ®Google Scholar
• Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011;11:20.
   PubMed Web of Science ®Google Scholar
• Oliveria SA, Koro CE, Yood MU, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes & Metabolic Syndrome. Clin Res Rev 2008; 2(1) :47–57.
   Google Scholar
• Wells GA. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
   Google Scholar
• Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–12.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
   PubMed Web of Science ®Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–48.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
   PubMed Web of Science ®Google Scholar
• Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol 2009;62:97–128.
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
   PubMed Web of Science ®Google Scholar
• Follmann M, Heinemann LA, Bauerfeind A, Garbe E. Treatment with potentially hepatotoxic drugs and the risk of hepatocellular carcinoma: results of a European case-control study. Pharmacoepidemiol Drug Saf 2000;9:417–22.
   PubMedGoogle Scholar
• Donadon V, Balbi M, Valent F, Avogaro A. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol 2010;16:3025–32.
   PubMed Web of Science ®Google Scholar
• Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010;33:1997–2003.
   PubMed Web of Science ®Google Scholar
• Chang CH, Toh S, Lin JW, Chen ST, Kuo CW, Chuang LM, Cancer risk associated with insulin glargine among adult type 2 diabetes patients–a nationwide cohort study. PLoS One 2011;6:e21368.
   PubMed Web of Science ®Google Scholar
• Hense HW, Kajüter H, Wellmann J, Batzler WU. Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort. Diabetol Metab Syndr 2011;3:15.
   PubMedGoogle Scholar
• Mella JM, Koch MF, Nine C, Mastai R, Barreto M, Celeste F, Drug-induced hepatocholangitis with characteristics of hepatocarcinoma. Prensa Med Argent 2007;94:510–14.
   Google Scholar
• Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3:1451–61.
   PubMed Web of Science ®Google Scholar
• Donadon V, Balbi M, Casarin P, Vario A, Alberti A. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin. World J Gastroenterol 2008;14:5695–700.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Taniguchi E, Morita Y, Shirachi M, Tateishi I, Nagata E, Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int 2010;30:479–86.
   PubMed Web of Science ®Google Scholar
• Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011;96:2601–8.
   PubMed Web of Science ®Google Scholar
• Gao C, Yao SK. Diabetes mellitus: a "true" independent risk factor for hepatocellular carcinoma? Hepatobiliary Pancreat Dis Int 2009;8:465–73.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012;35:299–304.
   PubMed Web of Science ®Google Scholar
• Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 2012;35:119–24.
   PubMed Web of Science ®Google Scholar
• Bosco JL, Antonsen S, Sørensen HT, Pedersen L, Lash TL. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2011;20:101–11.
   PubMed Web of Science ®Google Scholar
• Guppy A, Jamal-Hanjani M, Pickering L. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol 2011;7:727–36.
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G, Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011;34:2323–8.
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann NY Acad Sci 2011;1243:54–68.
   PubMed Web of Science ®Google Scholar
• Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, Metformin: taking away the candy for cancer? Eur J Cancer 2010;46:2369–80.
   PubMed Web of Science ®Google Scholar
• Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Metformin: Multi-faceted protection against cancer. Oncotarget 2011;2:896–917.
   PubMed Web of Science ®Google Scholar
• de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos Mazo DF, Lima VM, Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res 2008;38:159–65.
   PubMed Web of Science ®Google Scholar
• Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009;29:172–82.
   PubMed Web of Science ®Google Scholar